Unfortunately many companies avoid publishing news which most would find material using common sense. The most glaring omission is the failure to notify investors when a company receives a CRL letter from the FDA. The rationale is that the letter is not a rejection of the filing but rather a request for more information and testing. In the case of SequestOX the CRL was really a RIP.
The next newsworthy event for investors here will be the conference call at the end of the month when Nasrat will probably have to address the progress being made by KIrkov in selling and distributing the Adderall products. As for Lannett, parting is not sweet sorrow.
News 
Market Data 
Discover 
